# Mirada Medical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/mirada-medical

- Industry: Software
- Headquarters: Oxford, UK
- Website: www.mirada-medical.com
- Total disclosed funding: $7.8M
- Latest round: Series A (Apr 8, 2019)
- Investors on record: 2

## About

Mirada Medical Limited develops advanced imaging software designed to enhance cancer treatment precision. Their innovative technology improves accessibility and efficiency in diagnostic imaging workflows for healthcare providers.Mirada Medical Limited, founded in 2000, is based in Oxford, UK. The company specializes in advanced imaging solutions for cancer treatment. It has successfully completed a total of 4 funding deals, with the most recent being a Growth round in June 2022, which raised USD 20.00 mn from Apposite Capital. The total amount raised to date is also USD 20.00 mn. The CEO is Jon DeVries, and the company was founded by Hugh Bettesworth.Mirada Medical specializes in advanced imaging software that enhances the precision and personalization of cancer treatment. Their core products include Mirada XD™, a diagnostic imaging platform, and Simplicit90Y™, designed for interventional radiology and dosimetry. These solutions utilize AI-assisted workflows to streamline processes, particularly in PET/CT reporting, improving patient outcomes by making cancer care more accessible. Their client base includes hospitals and cancer centers primarily in the UK and the US, focusing on supporting clinicians in radiation oncology and diagnostic imaging.In the most recent year of 2023, Mirada Medical reported a revenue of USD 4,783,413.20, alongside an EBITDA of USD -4,759,906.60. The company’s revenue model is based on B2B transactions, primarily through software subscriptions and partnerships with healthcare institutions. Clients typically engage through structured agreements that involve licensing fees for products like Mirada XD™ and Simplicit90Y™, including setup costs and recurring fees for support and updates.Mirada Medical plans to utilize the USD 20.00 mn raised in their recent Growth funding round to expand their product offerings and enhance solutions for physicians. As part of their strategy, the company aims to introduce new products and enhance existing offerings, focusing on specific markets and regions for expansion. The funding will be directed towards achieving these objectives and delivering transformative solutions to improve cancer treatment outcomes.

## Funding rounds

- Series A, Apr 8, 2019, $7.8M — Albion Capital, Apposite Capital

## Investors

- Albion Capital — Series A
- Apposite Capital (https://capitalatlas.ai/funds/apposite-capital) — Series A